Results 41 to 50 of about 60,395 (277)

Preclinical Results of Camptothecin-Polymer Conjugate (IT-101) in Multiple Human Lymphoma Xenograft Models [PDF]

, 2009
Purpose: Camptothecin (CPT) has potent broad-spectrum antitumor activity by inhibiting type I DNA topoisomerase (DNA topo I). It has not been used clinically because it is water-insoluble and highly toxic.
Colcher, David, Davis, Mark E., Duringer, Julienne, Forman, Stephen J., Kretzner, Leo, Numbenjapon, Tontanai, Raubitschek, Andrew, Schluep, Thomas, Wang, Jianyi, Yen, Yun   +9 more
core   +1 more source

The potential role and application of PARP inhibitors in cancer treatment [PDF]

, 2009
Background: Since many anti-cancer agents act by inflicting DNA damage on tumour cells, there is increasing interest in the use of inhibitors of DNA repair to increase the cytotoxicity of these agents.
Chalmers, Anthony J
core   +2 more sources

Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy

Biomolecules, 2015
Most chemotherapy regimens contain at least one DNA-damaging agent that preferentially affects the growth of cancer cells. This strategy takes advantage of the differences in cell proliferation between normal and cancer cells.
Yang Xu, Chengtao Her
doaj   +1 more source

Organometallic iridium(III) anticancer complexes with new mechanisms of action: NCI-60 screening, mitochondrial targeting, and apoptosis [PDF]

, 2013
Platinum complexes related to cisplatin, cis-[PtCl2(NH3)2], are successful anticancer drugs; however, other transition metal complexes offer potential for combating cisplatin resistance, decreasing side effects, and widening the spectrum of activity ...
Bailey H. H., Ballestrero A., Bellamy W. T., Betanzos-Lara S., Bozic I., Bushra Qamar, Carew J. S., Castonguay A., Chan J., Constantini P., Dai Y., Degterev A., Dindo D., Doroshow J. H., Dyke M. W. Van, Fagan V., Finnilä S., Frank J. E., Fu Y., Fu Y., Gaiddon C., Garbutcheon-Singh K. B., Hannon M. J., Hartinger C. G., Hileman E. A., Holbeck S., Huo H., Ian Hands-Portman, Isolda Romero-Canelón, Jessica M. Hearn, Jordan M. A., Jungwirth U., Kelland L., Kerr J. F., Kroemer G., Lazebnik Y. A., Liu Z., Liu Z., Liu Z., Lu J.-J., McKeage M. J., Millar A. W., Monneret C., Nagata S., Park G. Y., Paull K., Perchellet E. M., Peter J. Sadler, Petrelli A., Pittella F., Porteous C. M., Pracharova J., Purewal M., Rai S. S., Rixe O., Saraste A., Shoemaker R. H., Shoemaker R. H., Siddik Z., Sidler D., Tsutsui T., Türk D., Van den Bogert C., Zalacaín M., Zhang Y.-W., Zhe Liu, Zhou D.-F., Zhu Z.   +67 more
core   +1 more source

Inhibition of Poly(ADP-Ribose) polymerase enhances the toxicity of 131I-Metaiodobenzylguanidine/Topotecan combination therapy to cells and xenografts that express the noradrenaline transporter [PDF]

, 2012
Targeted radiotherapy using [131I]meta-iodobenzylguanidine ([131I]MIBG) has produced remissions in some neuroblastoma patients. We previously reported that combining [131I]MIBG with the topoisomerase I (Topo-I) inhibitor topotecan induced long-term DNA ...
Babich, John W, Boyd, Marie, Champion, Sue, Gaze, Mark N, Mairs, Robert J, McCluskey, Anthony G, Pimlott, Sally L, Tesson, Mathias   +7 more
core   +1 more source

Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents. [PDF]

PLoS ONE, 2018
Recent studies have shown that HDAC inhibitors act synergistically with camptothecin derivatives in combination therapies. To exploit this synergy, new hybrid molecules targeting simultaneously topoisomerase I and HDAC were designed.
Raffaella Cincinelli, Loana Musso, Roberto Artali, Mario B Guglielmi, Ilaria La Porta, Carmela Melito, Fabiana Colelli, Francesco Cardile, Giacomo Signorino, Alessandra Fucci, Martina Frusciante, Claudio Pisano, Sabrina Dallavalle   +12 more
doaj   +1 more source

Genotoxic mixtures and dissimilar action: Concepts for prediction and assessment [PDF]

, 2013
This article has been made available through the Brunel Open Access Publishing Fund. This article is distributed under the terms of the creative commons Attribution license which permits any use, distribution, and reproduction in any medium, provided ...
A Bouslimi, A Elhajouji, Andreas Kortenkamp, AY Kocaman, CI Bliss, D Kirkland, E Hecker, K Drescher, K Hashimoto, K Hashimoto, M Faust, M Fenech, M Honma, M Marinovich, M Scholze, Martin Scholze, MC Berenbaum, MC Berenbaum, National Research Council, P Fowler, R Altenburger, S Ermler, S Loewe, Sibylle Ermler, T Backhaus, T Mosmann, W Slob, WK Lutz, WK Lutz, WK Lutz   +29 more
core   +2 more sources

Evaluation of the Anticancer and Biological Activities of Istaroxime via Ex Vivo Analyses, Molecular Docking and Conceptual Density Functional Theory Computations

Molecules, 2023
Cancer is a disease that occurs as a result of abnormal or uncontrolled growth of cells due to DNA damage, among many other causes. Certain cancer treatments aim to increase the excess of DNA breaks to such an extent that they cannot escape from the ...
Ege Gok, Naz Unal, Burcin Gungor, Gulderen Karakus, Savas Kaya, Pakize Canturk, Konstantin P. Katin   +6 more
doaj   +1 more source

Topoisomerase I inhibitors: clinical studies on oral administration and/or combinations with cisplatin [PDF]

, 1999
The topoisomerases were discovered in 1971, but it was not until the 1980s that the significance of these enzymes as potential therapeutic targets was appreciated. Topoisomerase I plays a crucial role in the normal replication of DNA.
Jonge, M.J.A. (Maja) de
core   +1 more source

Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper [PDF]

, 2016
Objectives: In this paper, we present a review of critical concepts and research perspectives and produce recommendations on the optimal use of pixantrone in non-Hodgkin lymphoma (NHL) by group discussion from an expert panel appointed by the Italian ...
Barosi, Giovanni, Corradini, Paolo, Martelli, Maurizio, Minotti, Giorgio, Oliva, Stefano, Spina, Michele, Tura, Sante, Zinzani, Pier Luigi   +7 more
core   +1 more source